Nothing Special   »   [go: up one dir, main page]

AU2000273378A1 - Therapeutic methods that target fractalkine or cx3cr1 - Google Patents

Therapeutic methods that target fractalkine or cx3cr1

Info

Publication number
AU2000273378A1
AU2000273378A1 AU2000273378A AU7337800A AU2000273378A1 AU 2000273378 A1 AU2000273378 A1 AU 2000273378A1 AU 2000273378 A AU2000273378 A AU 2000273378A AU 7337800 A AU7337800 A AU 7337800A AU 2000273378 A1 AU2000273378 A1 AU 2000273378A1
Authority
AU
Australia
Prior art keywords
fractalkine
cx3cr1
target
therapeutic methods
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000273378A
Inventor
Alisa E. Koch
James B. Rottman
Jeffrey H. Ruth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Northwestern University
Original Assignee
Millennium Pharmaceuticals Inc
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc, Northwestern University filed Critical Millennium Pharmaceuticals Inc
Publication of AU2000273378A1 publication Critical patent/AU2000273378A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2000273378A 2000-02-18 2000-08-30 Therapeutic methods that target fractalkine or cx3cr1 Abandoned AU2000273378A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18356800P 2000-02-18 2000-02-18
US60183568 2000-02-18
PCT/US2000/023837 WO2001060406A1 (en) 2000-02-18 2000-08-30 Therapeutic methods that target fractalkine or cx3cr1

Publications (1)

Publication Number Publication Date
AU2000273378A1 true AU2000273378A1 (en) 2001-08-27

Family

ID=22673365

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000273378A Abandoned AU2000273378A1 (en) 2000-02-18 2000-08-30 Therapeutic methods that target fractalkine or cx3cr1

Country Status (3)

Country Link
US (2) US20020054875A1 (en)
AU (1) AU2000273378A1 (en)
WO (1) WO2001060406A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7986806B2 (en) * 1994-11-16 2011-07-26 Digimarc Corporation Paper products and physical objects as means to access and control a computer or to navigate over or act as a portal on a network
EP1441684A4 (en) * 2001-11-07 2006-08-02 Millennium Pharm Inc Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
US7101852B2 (en) * 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
EP1520586A1 (en) * 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
ES2641815T3 (en) * 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Treatment for inflammatory diseases
US9172453B2 (en) 2005-10-27 2015-10-27 Qualcomm Incorporated Method and apparatus for pre-coding frequency division duplexing system
EP2262531A1 (en) * 2008-03-08 2010-12-22 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
JO3437B1 (en) * 2009-10-30 2019-10-20 Esai R & D Man Co Ltd Improved anti human Fraktalkine antibodies and uses thereof
WO2012078633A2 (en) 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
IL311502A (en) 2012-02-27 2024-05-01 Ablynx Nv Cx3cr1-binding polypeptides
EP2913060A1 (en) 2014-02-28 2015-09-02 Universite De Nice Sophia-Antipolis Inhibition of the fractalkine-receptor interaction for the treatment of atopic dermatitis
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
WO2019014122A1 (en) * 2017-07-08 2019-01-17 The Brigham And Women's Hospital, Inc. Methods to improve anti-angiogenic therapy and immunotherapy
WO2020190902A1 (en) * 2019-03-19 2020-09-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptors with enhanced tumor infiltration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69317883T2 (en) * 1992-11-17 1998-11-12 Icos Corp., Bothell, Wash. New seven-transmembrane receptor V28
US6107475A (en) * 1992-11-17 2000-08-22 Icos Corporation Seven transmembrane receptors
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
JPH10507646A (en) * 1995-06-07 1998-07-28 アイコス コーポレイション Chemokines and chemokine analogs derived from macrophages
WO1997042224A1 (en) * 1996-05-07 1997-11-13 Millennium Biotherapeutics, Inc. Neurotactin and uses therefor
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor

Also Published As

Publication number Publication date
WO2001060406A1 (en) 2001-08-23
US20020054875A1 (en) 2002-05-09
US20020055456A1 (en) 2002-05-09

Similar Documents

Publication Publication Date Title
GB2390417B (en) Target system
AU2002231352A1 (en) Sputtering target
AUPQ598700A0 (en) Weapon
AU2002224480A1 (en) Lace-less shoe
IL158993A0 (en) Recessed sputter target
AU2002360023A1 (en) Smoking implement
AU2001288271A1 (en) Methods for treating inflammatory diseases
AU2000273378A1 (en) Therapeutic methods that target fractalkine or cx3cr1
AU2001290685A1 (en) Methods for inhibiting inflammatory disease
AU2003245676A1 (en) Exhaustive selection or rna aptamers against complex targets
AU2001275184A1 (en) Sputtering target
AU2001295777A1 (en) Target
AU2002335667A1 (en) Modified reoviral therapy
AU2001277857A1 (en) Tumor necrosis factor-gamma
AU2001269257A1 (en) Target face
AU2001277236A1 (en) Shoe construction
AU2001284265A1 (en) Genetic study
GB0011164D0 (en) Target
AU2002228911A1 (en) Methods for inhibiting pain
GB0100151D0 (en) Methods of sputtering
AU2001284590A1 (en) Shoe
AU2003254043A1 (en) Antifungal therapeutic targets
GB0016009D0 (en) Target
AU2001276049A1 (en) Method of enabling the spacing of metal units
AU2001277093A1 (en) Methods for identifying therapeutic targets